Masimo (NASDAQ: MASI) kondigde vandaag de resultaten aan van een prospectieve, observationele studie gepubliceerd in Acta Paediatrica waarin onderzoekers van het kinderziekenhuis in Toronto de nauwkeurigheid evalueerden van plethysmografische respiration rate measurement (RRp®) met behulp van Masimo Rad-G™, een robuust, handheld apparaat, bij ondervoede, gehospitaliseerde kinderen in Nigeria.
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.
In an effort to treat patients currently suffering from COVID-19, researchers from Feinstein Institutes are collaborating on new clinical studies with biopharmaceutical leaders Gilead Sciences, Regeneron and Sanofi
The Feinstein Institutes for Medical Research, the research arm of Northwell Health, announced today the enrollment of three clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus.
Feinstein Institutes researchers are teaming up with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to identify effective treatments for patients currently hospitalized in moderate and severe conditions with COVID-19. The goal is to improve recovery and speed discharge from hospitals. The three Feinstein Institutes trials are offered to patients already admitted to Northwell Health hospitals with moderate to severe COVID-19. The trials are not currently available to the general public.
“We’ve joined with three outstanding companies to immediately begin clinical trials for patients now suffering from COVID-19 and are determined to do all we can to stop the virus in its tracks,” said Michael Dowling, president and CEO of Northwell Health.
While there is a nationwide push for an expedited Food and Drug Administration (FDA) approval process of these and other experimental COVID-19 therapies, Northwell Health and the Feinstein Institutes prioritize the safety of patients. The process of these formal trials will lead to accurate testing of these novel drugs prior to mainstream use.
With Gilead, the Feinstein Institutes will conduct two trials looking at the safety and efficacy of remdesivir (RDV), an investigational antiviral drug, designed to reduce the intensity and duration of COVID-19 in hospitalized patients. RDV has demonstrated positive effects on other viral pathogens such as MERS and SARS in vitro and in animal models. The first trial can accommodate up to 400 severe cases of COVID-19 globally and is a randomized study of two different durations of treatment with RDV, delivered intravenously. Researchers will look at clinically relevant endpoints in patients with severe manifestations of disease. The lead investigator on this study is Marcia Epstein, MD, Feinstein Institutes researcher and an infectious disease expert.
The other RDV trial in collaboration with Gilead is also a phase 3 study that will assess two different durations of treatment with RDV as compared to current standard of care in up to 600 patients with moderate COVID-19 globally. Researchers will look at clinical endpoints and time to discharge. The lead investigator on this study is Prashant Malhotra, MD, assistant professor in the Institute of Health Innovations & Outcomes Research at Feinstein, and an infectious disease expert.
In collaboration with Regeneron Pharmaceuticals and Sanofi, the Feinstein Institutes will conduct an adaptive randomized trial for approximately 400 severe or critical patients being hospitalized for the virus in multiple sites across the US. It will look at the safety and efficacy of sarilumab, a human antibody that may prevent the activity of a specific cytokine called interleukin-6 (IL-6) that is thought to be important in the development of complications of severe pneumonia in some COVID-19 patients.
The role of IL-6 is supported by preliminary data from a Chinese trial and based on those results which showed rapid reductions in fever in all patients, China recently updated its COVID-19 treatment guidelines and approved the use of that IL-6 inhibitor to treat patients with severe or critical disease. The study that the Feinstein Institutes will participate in is the first controlled trial in the U.S. to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients. The lead investigator on this study is Negin Hajizadeh, MD, assistant professor in the Institute of Health Innovations & Outcomes Research at Feinstein, and a pulmonary and critical care physician.
“As history has shown from past pandemics, medical research will lead in our nation’s ability to reverse the fatal spread of viruses,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “By teaming up with these outstanding pharmaceutical leaders, our researchers have the opportunity to help beat the Coronavirus by delivering cutting-edge care through clinical research at our Northwell Health hospitals.”
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit feinstein.northwell.edu.
About Northwell Health
Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, about 750 outpatient facilities and more than 13,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 70,000 employees – 16,000-plus nurses and 4,000 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.
The Thailand Board of Investment (BOI) said today that local and foreign investors had in 2020 filed a total of 1,717 applications for investment promotion, representing a combined investment value of 481.1 billion baht (USD16 billion), led by projects in the electric and electronics and the agriculture and food processing sectors, and a surge in the medical sector.
“The coronavirus outbreak represented both a challenge and an opportunity, and while the overall economy registered a slowdown in 2020, businesses that can continue to expand during the crisis, such as the medical sector, witnessed an increased number of investment applications,” Ms Duangjai Asawach, Secretary General of the BOI, told reporters. “The number of projects and the investment value reflect the success of the investment promotion measures we took in the past year to answer the needs of the market, especially in the medical masks, hygiene products, and medical rubber gloves segments.”
Applications for projects in the target industries, sectors of strategic importance for the country’s economic development, amounted to 230.7 billion baht, or 48% of the total value of applications. The top five sectors by value were: 1) electrical appliances and electronics with 50.3 billion baht worth of applications; 2) Agriculture and food processing with 41.1 billion baht; 3) automotive and parts with 37.8 billion baht; 4) Petrochemicals and Chemicals with 36 billion baht; and 5) Biotechnology with 30 billion baht.
The medical sector saw a noticeable increase of the value of applications which grew 165% from 2019 to 22.3 billion baht as a result of specials incentives offered by the BOI to this industry in support of Thailand’s efforts to manage the Covid-19 crisis. Investments in this sector came from both large companies and SMEs.
In regard to Foreign Direct Investment (FDI), some 907 project applications were filed in 2020 worth a total investment value of 213.2 billion baht. The FDI were led by Japanese companies, which topped the ranking both in terms of the number of applications, 211 projects, and in terms of combined investment value, 75.9 billion baht. Investments from China came in second with 31.5 billion baht investment value, followed by US with 24.6 billion baht investment value.
The Eastern Economic Corridor, or EEC area, which comprises the provinces of Chonburi, Rayong and Chachoengsao, attracted 453 projects applications filed by both local and foreign investors, worth a combined investment value of 208.7 billion baht.
Renewal of the measures to encourage the public listing of BOI-promoted companies
At a board meeting chaired by Prime Minister Gen Prayut Chan-ocha today, the BOI approved to renew the incentives offered to BOI-promoted companies to list on the Stock Exchange of Thailand (SET) or the Market for Alternative Investment (MAI) in order to get access to new funding sources, while participating to strengthen Thailand’s capital market and economy.
The scheme grants companies going public an additional 100% corporate income tax (CIT) exemption on the value of their investment (excluding cost of land and working capital). Projects which have already been granted BOI promotion and have started to generate income can still apply for these additional privileges and benefits on the condition they still have valid CIT exemption rights.
To be granted these additional privileges and benefits, companies must submit their applications by the end of December 2022. The companies must get listed on the SET or MAI before applying for promotion, but companies listed prior to the announcement of the measure are not eligible to this scheme.